Table 2.
List of primers used in this study.
| Characteristic | Total cohortN (Percentage) | Resectable* | Borderline resectable * | Unresectable* | P value |
|---|---|---|---|---|---|
| Total Number of patients | 375 | 242 | 88 | 45 | – |
| Median Age | 55 (range: 22-82). | 53 (22-78) | 57 (26-82) | 53(24-81) | 0.49 |
| Male : Female | 1.8:1 | 1.8:1 | 2.3:1 | 2.2:1 | – |
| Primary Site Right colon and Transverse colon Decending colon Sigmoid colon Rectum |
98 (26.13%) 7 (1.86%) 49(13.06%) 221(58.5%) |
– | _ | _ | – |
| Treatment groups Surgery Non Surgery |
217 (57.86%) 158 (42.13%) |
165(68.18%) 77 (31.81%) |
51 (57.95%) 37 (42.04%) |
1 (2.2%) 44 (97.77%) |
– |
| T Stage T1 T2 T3 T4 Tx |
42 (11.20%) 53 (14.13%) 221(58.93%) 55 (14.66%) 4 (1.06%) |
22 (9.09%) 32(13.32%) 150(61.98%) 36 (14.87%) 2 (0.8%) |
11 (12.5%) 12 (13.63%) 51 (57.95%) 14 (15.90%) 0 |
9 (2%) 9 (2%) 20 (44.44%) 5 (11.11%) 2 (4.44%) |
0.086 |
| Nodal stage N0 N1 N2 Nx |
109 (29.03%) 231 (61.6%) 31 (8.26%) 4 (1.06%) |
69 (28.51%) 147(60.74%) 24 (9.91%) 2 (0.8%) |
24 (27.27%) 60 (68.18%) 4 (4.5%) 0 |
16 (35.55%) 24 (53.33%) 3 (6.66 %) 2 (4.44%) |
0.116 |
| kRAS Mutation Wild Type Not Tested |
97 (25.86 %) 200(53.30%) 78 (20.8%) |
60 (24.79%) 119(49.17%) 63 (26.03%) |
25 (28.40%) 50 (56.81%) 13 (14.77%) |
12 (26.66%) 31 (68.88%) 2 (4.44%) |
– |
| Multiple liver metastasis (more than 1) | 205 | 84 (34.71%) | 77 (87.5%) | 44 (97.7%) | 0.01 |
| Number of liver lesions ≥ 4 | 64 | 2 (0.8%) | 35 (39.77%) | 27(60%) | <0.01 |
| Mean Size (Cumulative) of lesions | 3.58cm ±2.19 | 3.31 cm ±2.23 | 4.01 ±2.55 | 5.6cm ±1.8 | 0.01 |
| Size of lesion >5 cm | 70 | 5 (2.06%) | 26 (29.54%) | 39 (86.66%) | <0.01 |
| Distribution Unilobar Bilobar |
258 117 |
227 (93.80%) 15 (6.19%) |
31 (35.22%) 57 (64.77%) |
0 45 (100%) |
<0.01 |
| Neoadjuvant Chemotherapy | 237 | 104 (42.97%) | 88 (100%) | 45 (100%) | <0.0001 |
| Simultaneous Resections | 60 /224 (27.67 %) | 60(23.96%) | 0 | 0 | |
| Synchronous Metachronus |
247 128 |
143 (59.09%) 99 (40.90%) |
68 (77.27%) 20 (22.72%) |
36 (80%) 9 (20%) |
0.001 |
| Median CEA | 56 (IQR 2-112 ) | 11.5 IQR (4-42.8) | 14 (IQR :6.8-69.74) | 77(IQR 11-56) | 0.8 |
CEA, carcinoembryonic antigen.